Investor Overview

NASDAQ: XBIT0.034.79Data provided by Nasdaq.
Minimum 15 minutes delayed.

XBiotech is building on a foundation of remarkable new therapies, innovative approaches to commercialization and a commitment to realizing treatments for unmet medical needs worldwide.

Recent News
DateTitle 
01/26/18XBiotech Announces Presentation of Data from Phase 2 Study Evaluating MABp1 for the Treatment of Hidradenitis SuppurativaPrinter Friendly Version
01/25/18XBiotech Publishes Results in PLOS ONE for its True Human Antibody 514G3 Targeting S. aureusPrinter Friendly Version
01/19/18XBiotech Announces Presentation of Phase 2 Open Label Extension Study Data Evaluating MABp1 for the Treatment of Hidradenitis SuppurativaPrinter Friendly Version

Read more »

Upcoming Events

There are currently no events scheduled.

Read more »